NCT03557060View on ClinicalTrials.gov

NUCALA® Special Drug Use Investigation (EGPA, Long-term)

UnknownOBSERVATIONAL

Enrollment

300

Participants

Timeline

Start Date

June 25, 2018

Primary Completion Date

May 31, 2024

Study Completion Date

May 31, 2024

Conditions

Churg-Strauss Syndrome

Interventions

DRUG

Nucala

NUCALA injections will be administered to eligible subjects with diagnosis of EGPA. Dose unit, daily dose frequency, date of administration will be at the investigator discretion.

Trial Locations (1)

107-0052

GSK Investigational Site, Tokyo